A5024234619- Parkinson's Disease Mechanisms and Treatments
- Lysosomal Storage Disorders Research
- Autism Spectrum Disorder Research
- Nuclear Receptors and Signaling
- Alzheimer's disease research and treatments
- Neurological diseases and metabolism
- Neurological disorders and treatments
- Restless Legs Syndrome Research
- Gout, Hyperuricemia, Uric Acid
- Cholinesterase and Neurodegenerative Diseases
- Attention Deficit Hyperactivity Disorder
- Olfactory and Sensory Function Studies
- Histone Deacetylase Inhibitors Research
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune Neurological Disorders and Treatments
- Developmental Biology and Gene Regulation
- Carbohydrate Chemistry and Synthesis
- Prion Diseases and Protein Misfolding
- Multiple Sclerosis Research Studies
- Kruppel-like factors research
- Autophagy in Disease and Therapy
- TGF-β signaling in diseases
- Cellular transport and secretion
- Ginkgo biloba and Cashew Applications
- Biochemical Analysis and Sensing Techniques
National and Kapodistrian University of Athens
2014-2025
Eginition Hospital
2021-2025
University General Hospital Attikon
2015-2021
ABSTRACT Background G209A SNCA mutation carriers represent an important group of genetic PD. We describe motor and nonmotor features carriers. Methods Longitudinal clinical assessments over 2 years were collected in 22 symptomatic 8 asymptomatic Motor rating scales administered. Correlations performed between variables disease duration or age. Penetrance was calculated using Kaplan‐Meier survival curves. Results Asymptomatic did not manifest clear premotor symptoms, but often reported that...
Reduced expression of lysosomal-associated membrane protein 2a and heatshock-cognate 70 proteins, involved in chaperone-mediated autophagy glucocerebrosidase, is reported PD brains. The aim this study was to identify systemic alterations 2a, heatshock cognate-70, glucocerebrosidase levels/activity peripheral blood mononuclear cells from patients.Protein/mRNA levels were assessed patients genetically undetermined background, alpha-synuclein (G209A/A53T), or mutation carriers age-/sex-matched...
Background: The role of blood uric acid as a biomarker in symptomatic motor PD has been increasingly established the literature. Objective: Our present study assessed serum putative prodromal cohort [REM Sleep Behavior disorder (RBD) and Hyposmia] followed longitudinally. Methods: Longitudinal 5-year measurement data 39 RBD patients 26 Hyposmia with an abnormal DATSCAN imaging were downloaded from Parkinson’s Progression Markers Initiative database. These cohorts compared 423 de novo 196...
Abstract Background The p.A53T variant in the SNCA gene was considered, until recently, to be only causing familial Parkinson's disease (PD) Greek population. We identified a novel heterozygous p.A30G (c.89 C>G) pathogenic five affected individuals of three families, leading autosomal dominant PD. This study aims further explore presence and phenotypic expression this PD Methods Restriction fragment length polymorphism (RFLPs) used for genotyping 664 cases. Detailed clinical information...
Background Dance for Parkinson’s Disease (DfPD) is a dance program individuals with Parkinson disease (PD). There lack of knowledge about the effect this on frailty and sarcopenia experienced by patients PD. In addition, no randomized controlled trial to date has investigated either possible differential effects in-person versus online DfPD or clinical parameters in Greek Objective We aimed assess efficacy, safety, feasibility culturally tailored patient-centered offered both early- midstage...
IntroductionBlood uric acid represents an important biomarker in sporadic Parkinson's disease (PD). Whether levels change genetic forms of PD is beginning to be assessed. The aim the present study was evaluate differences serum level among patients harboring mutations glucocerebrosidase (GBA1) gene, PD, and healthy controls followed longitudinally.MethodsLongitudinal 2-year measurement data 120 GBA-PD have been downloaded from Progression Markers Initiative (PPMI) database. This cohort...
Introduction: Previous epidemiological evidence has established the co-occurrence of malignant melanoma (MM) and Parkinson’s disease (PD). Shared molecular mechanisms have been proposed to be implicated in this relationship. The aim present study was assess prevalence MM patients with sporadic genetic types PD, as well asymptomatic carriers PD-related genes. Methods: Data regarding past medical history concomitant 1416 PD (including 20 participants prodromal who phenoconverted PD), 275...
Background:Blood uric acid level represents an emerging biomarker in Parkinson's disease (PD). Whether levels change genetic forms of PD is just beginning to be explored. Objective:The aim the present study was assess differences serum among patients harbori ng p.A53T mutation alpha-synuclein gene, idiopathic PD, and healthy controls. Methods:Longitudinal 5-year measurement data 369 de novo 174 age- gender-matched controls have been downloaded from Progression Markers Initiative (PPMI)...
Cerebrospinal fluid (CSF) α-synuclein (ASYN) levels are emerging as a possible biomarker in number of neurodegenerative conditions; however, there has been little study such demyelinating conditions with neurodegeneration multiple sclerosis (MS). In this study, we aimed to assess CSF ASYN MS spectrum [clinically isolated syndrome (CIS) and MS] patients compare them those obtained control subjects benign neurological (BNC). We used recently developed, ultra-sensitive sandwich enzyme-linked...
Rapidly progressive dementia (RPD) is a clinical syndrome developing in <1 to 2 years. Recent progress RPD evaluation significant, so RPD's prevalence may change over time. The aim of our new case series was estimate the relative frequency RPDs' causative entities, considering recent advances diagnosis, and compare results with those previous report.We retrospectively reviewed medical records 47 patients who were referred Attikon University Hospital during 5-year period for suspected...
the apolipoprotein e4 allele (APOE4) constitutes an established genetic risk factor for Alzheimer's Disease Dementia (ADD). We aimed to explore frequency of APOE isoforms in Greek population Southern Greece.peripheral blood from 175 AD patients, 113 with mild cognitive impairment (MCI), and 75 healthy individuals. DNA isolation was performed a High Pure PCR Template Kit (Roche), followed by amplification real-time qPCR kit (TIB MolBiol) Roche's Light Cycler platform.APOE4 20.57% ADD group,...
Background: Previous studies have highlighted serum uric acid as a putative idiopathic Parkinson’s disease (iPD) biomarker. Only one study, so far, showed higher levels of in leucine-rich repeat kinase 2 (LRRK + 2) carriers compared to those who developed PD, however longitudinal comparison between LRRK2 PD and healthy controls (HC) has not been performed. Objective: The aim this study was determine whether there are differences iPD, HC their association with motor non-motor features....
Background and Objectives: The phenotype of p.A53T-SNCA Parkinson's Disease (PD) mutation carriers appears more severe than that iPD patients, however comprehensive comparative prospective studies are lacking. Here we conducted a longitudinal study to investigate, using multiple parameters, the progression motor nonmotor features p.A53T-PD compared iPD. Methods: Longitudinal 3-year data, concerning both non-motor features, 16 48 iPD, matched for age disease duration at baseline, were...